CURx Pharmaceuticals Announces License Agreement with Gilead Sciences

    CURx Pharmaceuticals Announces License Agreement with Gilead Sciences

PR Newswire

SAN DIEGO, Feb. 19, 2014

SAN DIEGO, Feb. 19, 2014 /PRNewswire/ -- CURx Pharmaceuticals today announced
it has entered into a global license agreement with Gilead Sciences, Inc. for
development of Fosfomycin:Tobramycin for Inhalation (FTI) to treat Pseudomonas
aeruginosa lung infection in cystic fibrosis (CF) patients. FTI is ready for
Phase III clinical trials, having successfully completed a Phase II trial in
CF patients.

(Logo: http://photos.prnewswire.com/prnh/20140212/MM64137LOGO)

"This is a great acquisition for CURx Pharmaceuticals which enables us to
expand our portfolio and also to provide another inhaled therapeutic to the
cystic fibrosis community", commented Dinu Sen, CEO and founder of CURx.
"Clinical trials in CF patients with Pseudomonas aeruginosa infection have
demonstrated FTI's safety and efficacy. Future trials may pave the way for its
use against a range of bacterial infections in CF - there is an unmet need for
antibiotics with such characteristics."

"Lung infections continue to be a serious problem for individuals with cystic
fibrosis," commented Dr. Drucy Borowitz, Director of the Cystic Fibrosis
Center of Western New York. "If further studies confirm that (FTI) is safe and
efficacious it will be a significant addition to improving the health of
people with CF." Dr. Patrick Flume, Director of the Cystic Fibrosis Center at
Medical University of South Carolina added "Currently we have two drugs
approved in the US for use in CF patients, but there remains a need for more
options. The CF community welcomes the development of new treatment options
such as FTI."

About FTI
FTI is a combination of fosfomycin and tobramycin, antibiotics well
characterized for safety and anti-bacterial activity. FTI is formulated as a
liquid for inhalation with an aerosol device. In Phase II clinical trials FTI
was shown to be safe and to effectively maintain improvement in lung function
achieved with Cayston in CF patients with Pseudomonas aeruginosa infection.
FTI has demonstrated antibiotic activity against multiple pathogenic bacteria,
including methicillin-resistant Staphylococcus aureus (MRSA), in preclinical
studies.

About cystic fibrosis
Cystic fibrosis is a hereditary disease affecting the lungs and digestive
system of 30,000 children and adults in the US and 70,000 worldwide. Chronic
bacterial infections in the lungs of CF patients are common and can be life
threatening if not adequately treated. Pseudomonas aeruginosa infects the
lungs of half of all CF patients, while methicillin-resistant Staphylococcus
aureus (MRSA) infects the lungs of about a quarter of CF patients.

About CURx Pharmaceuticals
San Diego-based CURx Pharmaceuticals specializes in developing late-stage
therapeutics with high medical need. In August 2013 CURx Pharmaceuticals
licensed intravenous topiramate from Ligand Pharmaceuticals, Inc. for
treatment of hospitalized epilepsy patients unable to take oral medication.
Please visit www.curxpharma.com for more information.

Forward-Looking Statements
This news release contains forward-looking statements. These statements are
subject to known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the statements made.
Factors that might cause such a difference include, among others, the
completion of clinical trials, the FDA and other foreign review processes and
other governmental regulation, CURx Pharmaceuticals' ability to successfully
develop and commercialize drug candidates, competition from other
pharmaceutical companies, the ability to effectively market products, and
other factors. CURx Pharmaceuticals undertakes no duty to update
forward-looking statements.

SOURCE CURx Pharmaceuticals

Website: http://www.curxpharma.com
Contact: Stephen J. Taylor, 858-242-1554, staylor@curxpharma.com
 
Press spacebar to pause and continue. Press esc to stop.